Cargando…

Advances in Pancreatic Cancer Treatment by Nano-Based Drug Delivery Systems

Pancreatic cancer represents one of the most lethal cancer types worldwide, with a 5-year survival rate of less than 5%. Due to the inability to diagnose it promptly and the lack of efficacy of existing treatments, research and development of innovative therapies and new diagnostics are crucial to i...

Descripción completa

Detalles Bibliográficos
Autores principales: Viegas, Cláudia, Patrício, Ana B., Prata, João, Fonseca, Leonor, Macedo, Ana S., Duarte, Sofia O. D., Fonte, Pedro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536303/
https://www.ncbi.nlm.nih.gov/pubmed/37765331
http://dx.doi.org/10.3390/pharmaceutics15092363
_version_ 1785112833906704384
author Viegas, Cláudia
Patrício, Ana B.
Prata, João
Fonseca, Leonor
Macedo, Ana S.
Duarte, Sofia O. D.
Fonte, Pedro
author_facet Viegas, Cláudia
Patrício, Ana B.
Prata, João
Fonseca, Leonor
Macedo, Ana S.
Duarte, Sofia O. D.
Fonte, Pedro
author_sort Viegas, Cláudia
collection PubMed
description Pancreatic cancer represents one of the most lethal cancer types worldwide, with a 5-year survival rate of less than 5%. Due to the inability to diagnose it promptly and the lack of efficacy of existing treatments, research and development of innovative therapies and new diagnostics are crucial to increase the survival rate and decrease mortality. Nanomedicine has been gaining importance as an innovative approach for drug delivery and diagnosis, opening new horizons through the implementation of smart nanocarrier systems, which can deliver drugs to the specific tissue or organ at an optimal concentration, enhancing treatment efficacy and reducing systemic toxicity. Varied materials such as lipids, polymers, and inorganic materials have been used to obtain nanoparticles and develop innovative drug delivery systems for pancreatic cancer treatment. In this review, it is discussed the main scientific advances in pancreatic cancer treatment by nano-based drug delivery systems. The advantages and disadvantages of such delivery systems in pancreatic cancer treatment are also addressed. More importantly, the different types of nanocarriers and therapeutic strategies developed so far are scrutinized.
format Online
Article
Text
id pubmed-10536303
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105363032023-09-29 Advances in Pancreatic Cancer Treatment by Nano-Based Drug Delivery Systems Viegas, Cláudia Patrício, Ana B. Prata, João Fonseca, Leonor Macedo, Ana S. Duarte, Sofia O. D. Fonte, Pedro Pharmaceutics Review Pancreatic cancer represents one of the most lethal cancer types worldwide, with a 5-year survival rate of less than 5%. Due to the inability to diagnose it promptly and the lack of efficacy of existing treatments, research and development of innovative therapies and new diagnostics are crucial to increase the survival rate and decrease mortality. Nanomedicine has been gaining importance as an innovative approach for drug delivery and diagnosis, opening new horizons through the implementation of smart nanocarrier systems, which can deliver drugs to the specific tissue or organ at an optimal concentration, enhancing treatment efficacy and reducing systemic toxicity. Varied materials such as lipids, polymers, and inorganic materials have been used to obtain nanoparticles and develop innovative drug delivery systems for pancreatic cancer treatment. In this review, it is discussed the main scientific advances in pancreatic cancer treatment by nano-based drug delivery systems. The advantages and disadvantages of such delivery systems in pancreatic cancer treatment are also addressed. More importantly, the different types of nanocarriers and therapeutic strategies developed so far are scrutinized. MDPI 2023-09-21 /pmc/articles/PMC10536303/ /pubmed/37765331 http://dx.doi.org/10.3390/pharmaceutics15092363 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Viegas, Cláudia
Patrício, Ana B.
Prata, João
Fonseca, Leonor
Macedo, Ana S.
Duarte, Sofia O. D.
Fonte, Pedro
Advances in Pancreatic Cancer Treatment by Nano-Based Drug Delivery Systems
title Advances in Pancreatic Cancer Treatment by Nano-Based Drug Delivery Systems
title_full Advances in Pancreatic Cancer Treatment by Nano-Based Drug Delivery Systems
title_fullStr Advances in Pancreatic Cancer Treatment by Nano-Based Drug Delivery Systems
title_full_unstemmed Advances in Pancreatic Cancer Treatment by Nano-Based Drug Delivery Systems
title_short Advances in Pancreatic Cancer Treatment by Nano-Based Drug Delivery Systems
title_sort advances in pancreatic cancer treatment by nano-based drug delivery systems
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536303/
https://www.ncbi.nlm.nih.gov/pubmed/37765331
http://dx.doi.org/10.3390/pharmaceutics15092363
work_keys_str_mv AT viegasclaudia advancesinpancreaticcancertreatmentbynanobaseddrugdeliverysystems
AT patricioanab advancesinpancreaticcancertreatmentbynanobaseddrugdeliverysystems
AT pratajoao advancesinpancreaticcancertreatmentbynanobaseddrugdeliverysystems
AT fonsecaleonor advancesinpancreaticcancertreatmentbynanobaseddrugdeliverysystems
AT macedoanas advancesinpancreaticcancertreatmentbynanobaseddrugdeliverysystems
AT duartesofiaod advancesinpancreaticcancertreatmentbynanobaseddrugdeliverysystems
AT fontepedro advancesinpancreaticcancertreatmentbynanobaseddrugdeliverysystems